Hausarztpraxis Voss,
"9.34 days’ life-expectancy gained. Clinical criteria/FH-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 more cost-effective than…
"9.34 days’ life-expectancy gained. Clinical criteria/FH-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 more cost-effective than…
Conclusions Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is more cost-effective than any clinical criteria/FH-b…
Cancer gene screening is more cost effective in the general population than for high-risk groups: http://bit.ly/2FTLmEu